Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS- 986177 in Participants With Normal Renal Function and Participants With Moderate and Severe Renal Impairment

Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.

Inclusion Criteria:

• Participants in Groups B and C will be classified by renal function by eGRF at screening and confirmed on Day -1
• Participants in Group A will be healthy participants as determined by no significant deviations in normal medical and surgical history and assessments
• Participants in Group A must have a body mass index of 18.0 to 32.0 kg/m2, inclusive
• Females must be of non-childbearing potential

Exclusion Criteria:

• Participants in Groups B and C cannot have an indwelling catheter for hemodialysis
• Participants in Groups B and C cannot have had, nor be waiting for, an organ transplant

Other protocol defined inclusion and exclusion criteria could apply